



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com
CIN NO. L24231MH1997PLC422233

August 13, 2025

To
The Manager,
Corporate Relations Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code - 524506

Sub: Outcome of Board meeting held on August 13, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other regulations if applicable, we hereby inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, August 13, 2025, inter alia, considered and approved:

1. Unaudited Financial Results for quarter ended June 30, 2025, along with the Limited Review Report of the Auditors thereon:

The Board of Directors have approved the Unaudited Financial Results (Standalone) for the quarter ended June 30, 2025, along with the Limited Review Report of the Auditors thereon.

The said Unaudited Financial Results prepared in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 together with the Limited Review Report for the quarter ended June 30, 2025 are enclosed herewith. **Annexure A.**

2. Confirmed and fixed Date of 43rd Annual General Meeting:

43rd Annual General Meeting will be convened on September 26, 2025 Further details of the AGM will be provided in the notice of the AGM which will be issued in due course.

3. Appointment of Statutory Auditor:

The Board of Directors upon completion of term of existing statutory auditor M/s M. A. Parekh & Associates, Chartered Accountants and based on the recommendation of the Audit Committee, has approved the appointment of M/s. S C Mehra & Associates LLP, Chartered Accountants as statutory auditors of the Company for a period of 05(five) consecutive years commencing from FY 2025-26 till 2029-30, subject to approval of the members at the ensuing Annual General Meeting.



The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure B**.

4. Alteration of Object Clause:

The Board of Directors have considered and approved alteration of object clause of the Memorandum of Association (MoA).

In Accordance with the requirements of the SEBI (LODR) Regulations, 2015 **Annexure C** is enclosed herewith.

5. Approval of Director Report :

The Director Report alongwith relevant annexures for the Financial Year ended March 31, 2025 was considered and approved.

The meeting was started at 02:30 p.m. and concluded at 04:30 p.m.

Kindly take the above on your record and disseminate the same for information of investors.

Thanking you,

Yours faithfully,

For Coral Laboratories Limited

Dhwani Desai
Company Secretary & Compliance Officer

Encl.: as above



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com
CIN NO. L24231MH1997PLC422233

Statement of Standalone Unaudited Financial Results for Ort ended 30th June 2025

(Rs. in Lakhs) (Except Figures in EPS)

Sr. No	Particulars (Refer Notes Below)	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Income				
	(a) Revenue from Operations	1882.14	2813.47	3165.58	11500.53
	(b) Other Income	204.81	248.14	156.11	910.86
2	Total income	2086.96	3061.60	3321.68	12411.39
3	Expenses				
	(a) Cost of Materials consumed	833.30	1139.16	1180.42	4814.32
	(b) Purchase of stock-in-trade	81.89	42.54	70.21	156.15
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-41.46	275.38	92.62	331.50
	(d) Employee benefits expense	342.12	383.20	358.99	1473.71
	(e) Depreciation and amortisation expense	45.32	50.61	49.39	201.06
	(f) Financial Cost	5.79	3.86	2.84	9.76
	(g) Other expenses	448.06	704.72	389.77	2100.91
	Total Expenses	1715.03	2599.48	2144.26	9087.41
4	Profit from operations before exceptional items and tax	371.93	462.13	1177.43	3323.98
5	Exceptional Items (Provision of Income tax of earlier year)	0.00	76.96	-	76.96
6	Profit from ordinary activities before tax	371.93	385.16	1177.43	3247.02
7	Tax expense				
	(a) Current Tax	115.00	110.00	295.00	833.00
	(b) Deferred Tax	0.50	-7.54	2.00	-1.54
8	Profit from Continuing Operation	256.43	282.71	880.43	2415.56
9	Profit From discontinuing operations				
10	Profit for the period	256.43	282.71	880.43	2415.56
11	Other Comprehensive Income				
A	(i) Items that will not be reclassified to profit and loss	563.15	-1256.63	874.01	26.80
	(ii) Income tax relating to income that will not be reclassified to profit and loss	-	-	-	-
12	Total Comprehensive income for the period (Comprising profit and loss and other Comprehensive Income for the period)	819.58	-973.93	1754.44	2442.37
13	Paid up Equity Share Capital (Face Value Rupees 10 per share)	357.26	357.26	357.26	357.26
14	Reserve excluding Revaluation reserve as per balance sheet of the previous accounting year	0.00	0.00	0.00	19763.32
15	Earnings Per Share (before extraordinary items)				
	(of Rs.10/- each):				
	(a) Basic	7.18	7.91	24.64	67.61
	(b) Diluted	7.18	7.91	24.64	67.61
	Earnings Per Share (after extraordinary items)				
	(of Rs.10/- each) :				
	(a) Basic	7.18	7.91	24.64	67.61
	(b) Diluted	7.18	7.91	24.64	67.61

For Coral Laboratories Limited



Gurish Dhamija
Gurish Dhamija
Wholetime Director
DIN : 07798455

Sushma Kadkade
Sushma Kadkade
Director & CFO
DIN : 07791735

Place : Mumbai
Date : August 13, 2025



CORAL LABORATORIES LTD

AN ISO 9001: 2008 CERTIFIED ORGANIZATION



REGD. OFFICE : #3B, Patanwala Compound, Opp. Shreyas Cinema, L.B.S. Marg, Ghatkopar (West), Mumbai - 400 086. India
Tel. : +91-22-2500 5245, 2500 8208, 2500 5246. • Fax : +91-22-2500 4893. • E-mail : accounts@corallab.com • Website : www.corallab.com
CIN NO. L24231MH1997PLC422233

NOTES

- 1 The Unaudited Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and were approved by the Board of Directors of the Company at their respective meetings held on August 13, 2025

This statement is as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These unaudited financial results of the Company were prepared in accordance with the Indian Accounting

- 2 Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities Exchange Board of India ("SEBI").
- 3 The Statutory Auditors have carried out the limited review of the financial results of the Company.
- 4 The Company has only one segment viz. "Formulations" as per Accounting Standard 17 of ICAI.
- 5 Corresponding quarter/year ended figures have been regrouped/reclassified wherever necessary to confirm to the classification of the current period.
- 6 Details of Investor Complaints for the Quarter:
Beginning: Nil Received: Nil Disposed: Nil Pending: Nil

For Coral Laboratories Limited


Girish Dhameja
Wholetime Director
DIN : 07798455


Sushma Kadkade
Director & CFO
DIN : 07791735

Place : Mumbai
Date : August 13, 2025





Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of the Company, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors
Coral Laboratories Limited

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **CORAL LABORATORIES LIMITED** ("the Company"), for the quarter ended June 30, 2025, ("the statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the Indian Accounting Standard 34 "Interim Financial reporting" ("Ind AS 34") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. A. Parekh & Associates
Chartered Accountants

FRN: 121973W

Manish Parekh
Proprietor
M No. 044911
Place: Mumbai

Date: 13th August, 2025

UDIN: 25044911BMINH5921





Annexure B

Information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Appointment of Statutory Auditor

Sr No.	Particulars	Description
1.	Name	M/s. S C Mehra & Associates LLP
2.	Designation	Statutory Auditor
3.	Reason for change	Appointment. Existing Auditor M/s M. A. Parekh & Associates retires at the conclusion of 43 rd AGM.
4.	Date of appointment/ cessation & terms of appointment	Appointment with effect from conclusion of 43 rd AGM to be held on September 26, 2025 for five years from FY 2025-26 to FY 2029-30
5.	Brief Profile	M/s S C Mehra & Associates, combines the international reach, depth and expertise of the large firms with the personal attention, value for money focus and relationship approach of the smaller firms. This service focus has made us the leading firm in each of our chosen area and the business advisers of choice to dynamic Indian businesses and their owners, when they seek to unlock their potential for growth through global expansion, global capital or global acquisitions. We render wide range of comprehensive professional services PAN India which inter alia, includes Assurance Services, Management Consultancy, Subsidy, Tax consultancy, Accounting, Corporate Finance, Risk Advisory Services, Manpower Management, Secretarial services etc. Our team consists of distinguished Chartered Accountants, Corporate Financial Advisors, Risk advisors and Tax consultants.
6.	Disclosure of relationship between directors	Not applicable (Statutory Auditor is not related to any Directors of the company)



Information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Retirement of Statutory Auditor

Sr No.	Particulars	Description
1.	Name	M/s M. A. Parekh & Associates
2.	Designation	Statutory Auditor
3.	Reason for change	Cessation due to completion of term of existing statutory auditor
4.	Date of appointment/cessation & terms of appointment	Completion of term of existing statutory auditor M/s M. A. Parekh & Associates, Chartered Accountants on conclusion of ensuing AGM
5.	Brief Profile	NA
6.	Disclosure of relationship between directors	Not applicable



Annexure C

Information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held on Wednesday, 13th August, 2025 have approved the alteration of object clause of the Memorandum of Association of the company subject to the approval of shareholders of the company.

Approval of the shareholders of the Company shall be taken at the Annual General Meeting of the Company.

Further, the brief details of alteration in MOA as required under Regulation 30 read with Part A of the Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as follows:

Adding new clause in Main object:

3. To carry on the business as manufactures, producers, makers, refiners, processors, formulators, importers, exporters, traders and dealers extract buy, sell, resell, barter, transport and store in pharmaceutical, antibiotic, medicinal, chemical, biological, immunological contraceptive serological, pathological and therapeutic used for treatment and healthcare of human being and animals.
4. To carry on the business as manufactures, producers, makers, refiners, processors, formulators, importers, exporters, traders and dealers extract buy, sell, resell, barter, transport and store in basic drugs, intermediates, vaccines, tonics, antibiotic, enzymes, steroids, vitamin, hormones, biosciences, biological & immunological chemicals, toxin-binders, yeasts, granules, sprays, droppers, veterinary medicine, aqua medicine, herbal products their by-products, residues, mixtures, premix, feed additives, vaccines, preparations and accessories used for treatment and healthcare of human being and animals.



Annexure C

Information as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors in their meeting held on Wednesday, 13th August, 2025 have approved the alteration of object clause of the Memorandum of Association of the company subject to the approval of shareholders of the company.

Approval of the shareholders of the Company shall be taken at the Annual General Meeting of the Company.

Further, the brief details of alteration in MOA as required under Regulation 30 read with Part A of the Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as follows:

Adding new clause in Main object:

3. To carry on the business as manufactures, producers, makers, refiners, processors, formulators, importers, exporters, traders and dealers extract buy, sell, resell, barter, transport and store in pharmaceutical, antibiotic, medicinal, chemical, biological, immunological contraceptive serological, pathological and therapeutic used for treatment and healthcare of human being and animals.
4. To carry on the business as manufactures, producers, makers, refiners, processors, formulators, importers, exporters, traders and dealers extract buy, sell, resell, barter, transport and store in basic drugs, intermediates, vaccines, tonics, antibiotic, enzymes, steroids, vitamin, hormones, biosciences, biological & immunological chemicals, toxin-binders, yeasts, granules, sprays, droppers, veterinary medicine, aqua medicine, herbal products their by-products, residues, mixtures, premix, feed additives, vaccines, preparations and accessories used for treatment and healthcare of human being and animals.